CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study
Objective: To test if alpha-synuclein (α-syn) levels in CSF, plasma and saliva predict PD status in the BioFind cohort, and to test whether α-syn levels…NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders
Objective: The objective of NS-PARK/FCRIN network (http://www.parkinson.network/) is to facilitate and stimulate clinical academic and industrial research in France in the field of Parkinson's disease…Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service
Objective: To describe the incorporation of a prescribing pharmacist into a Multi-disciplinary Parkinson's clinic based in a University Hospital Background: Evidence shows that a multidisciplinary…Prognosis and end-of-life status after emergency admissions in patients with Parkinson disease: a Japanese single center retrospective study
Objective: To investigate the status after the emergency admissions and to determine the cause and location of death in patients with Parkinson disease (PD). Background:…Effects of a Aquatic Dual Task Activity Program on the Quality of Life and Activities of Daily Living in Individuals with Parkinson’s Disease
Objective: To verify the effect of an aquatic Dual Task (DT) aquatic exercise program on quality of life (QOL), Activities of Daily Living activities (ADL) of…Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…5-year results from the NSTAPS trial: comparing bilateral deep brain stimulation of the globus pallidus pars interna versus the subthalamic nucleus for advanced Parkinson’s disease.
Objective: Comparing motor, cognitive, and psychiatric outcome 5 years after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) and the subthalamic…Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.
Objective: To report enrollment and tolerability data of mirabegron treatment in PD patients with OAB. Background: Lower urinary tract symptoms in PD have an estimated…ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study
Objective: To evaluate whether patient perceived improvement of Parkinson’s disease (PD) symptoms was associated with improvement in efficacy endpoints (mean daily OFF time and ON…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 155
- Next Page »